Statins has 6 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Diltiazem Hydrochloride, Fenofibrate, Fenofibric Acid. Patients taking Statins should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 4
- Moderate
- 2
Major (4)
- Statins + Diltiazem Hydrochloride— Increased risk of myopathy and rhabdomyolysis with statins metabolized by CYP3A4. Limit simvastatin to 10 mg daily and d…
- Statins + Fenofibrate— Fibrates may cause myopathy when given alone. Risk of myopathy and rhabdomyolysis is increased with concomitant use of f…
- Statins + Fenofibric Acid— Fibrates may increase risk of myopathy and rhabdomyolysis when used concomitantly with statins. Monitor patients for sig…
- Statins + Niacin— Caution should be used when prescribing niacin with statins as these agents can increase risk of myopathy/rhabdomyolysis…
Moderate (2)
- Statins + Lanthanum Carbonate— Lanthanum carbonate may reduce bioavailability of statins. Do not administer within 2 hours of lanthanum carbonate dosin…
- Statins + Maralixibat Chloride— Maralixibat may decrease oral absorption of statins as OATP2B1 inhibitor. Monitor drug effects of statins as needed.